Oncolytic adenovirus treatment of a patient with refractory neuroblastoma

Authors

  • Sari Pesonen Cancer Gene Therapy Group, Transplantation Laboratory and Finnish Institute of Molecular Medicine, University of Helsinki, Finland; Haartman Institute, University of Helsinki, Finland
  • Heikki Helin HUSLAB, Helsinki University Central Hospital, Finland; Department of Pathology, Helsinki University Central Hospital, Finland
  • Petri Nokisalmi Cancer Gene Therapy Group, Transplantation Laboratory and Finnish Institute of Molecular Medicine, University of Helsinki, Finland; Haartman Institute, University of Helsinki, Finland
  • Sophie Escutenaire Cancer Gene Therapy Group, Transplantation Laboratory and Finnish Institute of Molecular Medicine, University of Helsinki, Finland; Haartman Institute, University of Helsinki, Finland
  • Camilla Ribacka Cancer Gene Therapy Group, Transplantation Laboratory and Finnish Institute of Molecular Medicine, University of Helsinki, Finland; Haartman Institute, University of Helsinki, Finland
  • Merja Sarkioja Cancer Gene Therapy Group, Transplantation Laboratory and Finnish Institute of Molecular Medicine, University of Helsinki, Finland; Haartman Institute, University of Helsinki, Finland
  • Vincenzo Cerullo Cancer Gene Therapy Group, Transplantation Laboratory and Finnish Institute of Molecular Medicine, University of Helsinki, Finland; Haartman Institute, University of Helsinki, Finland
  • Kilian Guse Cancer Gene Therapy Group, Transplantation Laboratory and Finnish Institute of Molecular Medicine, University of Helsinki, Finland; Haartman Institute, University of Helsinki, Finland
  • Gerd Bauerschmitz Cancer Gene Therapy Group, Transplantation Laboratory and Finnish Institute of Molecular Medicine, University of Helsinki, Finland; Haartman Institute, University of Helsinki, Finland; Department of Obstetrics and Gynecology, Duesseldorf University Medical Center, Heinrich-Heine University, Germany
  • Leena Laasonen Helsinki Medical Imaging Center, University of Helsinki, Finland
  • Teemu Kantola Department of Anesthesiology, Helsinki University Central Hospital, Finland
  • Ari Ristimaki Cancer Gene Therapy Group, Transplantation Laboratory and Finnish Institute of Molecular Medicine, University of Helsinki, Finland; Department of Pathology, Helsinki University Central Hospital, Finland; Genome Scale Biology Program, Biomedicum Helsinki, Finland
  • Maria Rajecki Cancer Gene Therapy Group, Transplantation Laboratory and Finnish Institute of Molecular Medicine, University of Helsinki, Finland; Haartman Institute, University of Helsinki, Finland
  • Minna Oksanen Cancer Gene Therapy Group, Transplantation Laboratory and Finnish Institute of Molecular Medicine, University of Helsinki, Finland; Haartman Institute, University of Helsinki, Finland
  • Elina Haavisto Cancer Gene Therapy Group, Transplantation Laboratory and Finnish Institute of Molecular Medicine, University of Helsinki, Finland; Haartman Institute, University of Helsinki, Finland
  • Anna Kanerva Cancer Gene Therapy Group, Transplantation Laboratory and Finnish Institute of Molecular Medicine, University of Helsinki, Finland; Haartman Institute, University of Helsinki, Finland; Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Finland and
  • Timo Joensuu Docrates Oncology Hospital, Helsinki, Finland
  • Akseli Hemminki Cancer Gene Therapy Group, Transplantation Laboratory and Finnish Institute of Molecular Medicine, University of Helsinki, Finland; Haartman Institute, University of Helsinki, Finland

DOI:

https://doi.org/10.3109/02841860903071369

Abstract

No abstract available

Downloads

Download data is not yet available.

Downloads

Published

2010-01-01

How to Cite

Pesonen, S., Helin, H., Nokisalmi, P., Escutenaire, S., Ribacka, C., Sarkioja, M., … Hemminki, A. (2010). Oncolytic adenovirus treatment of a patient with refractory neuroblastoma. Acta Oncologica, 49(1), 120–122. https://doi.org/10.3109/02841860903071369